1. Generics Bulletin
  2. >>Products
  3. >>Generics

Amarin Investor Heat Intensifies, Despite ‘Unprecedented’ Vascepa Fortitude

Four Generic Icosapent Ethyl Products Have Only 40% Market Share

 
• By Dean Rudge

The brouhaha between Amarin and its largest shareholder has continued apace, with a smorgasbord of verbal volleys launched against the company, ahead of Amarin’s general meeting of shareholders later this month.

Amarin
Amarin are standing tall on Vascepa record • Source: Shutterstock

Amarin’s largest shareholder, Sarissa Capital, has continued its broadside at the company for “wasting” the value of Vascepa (icosapent ethyl) – in response to Amarin insisting that its current market share for the purified fish oil cardiovascular brand was “unprecedented for any drug after two years of generic competition.”

According to the originator’s latest data, Vascepa continues to hold a 60% share of all icosapent ethyl prescriptions written in...

Welcome to Generics Bulletin

Create an account to read this article

Already a subscriber?

More from Generics

Medicines UK’s Samuels: Off-Patent Drugs Are Finally Gov’s Priority But The Picture Still ‘Nuanced’

 
• By Urtė Fultinavičiūtė

The importance of generic and biosimilar medicines is being recognized by the UK government for the first time. But, as Medicines UK’s CEO Mark Samuels tells Generics Bulletin, companies are still facing multiple hurdles in the market.

BC Partners Bids For Biogaran Buyout – But Will It Face French Pushback?

 
• By Dave Wallace

Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?

Generics Bulletin’s Top 50 Ranking For 2025

 
• By Dave Wallace

This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

The Generics Bulletin Top 50, Part Three: New Firms Enter Global Grouping

 
• By Dave Wallace

In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.

More from Products

Generics Bulletin’s Top 50 Ranking For 2025

 
• By Dave Wallace

This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

The Generics Bulletin Top 50, Part Three: New Firms Enter Global Grouping

 
• By Dave Wallace

In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.

Latest EMA Biosimilar Nods Come For Henlius, Alteogen And Biocon

 
• By Dave Wallace

Denosumab, aflibercept and ustekinumab biosimilars received positive opinions from the EMA’s CHMP at its meeting in July, along with an Opsumit generic from Accord.